

Personalized breast health plans start with knowing your patients' cancer risks



According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), women with an increased risk for breast cancer may need earlier or advanced breast cancer screening and/or to consider risk-reducing options.¹⁻³

Screening Plan by Risk Level ¹⁻³	Percentage of Women		
	General Population Risk ¹	Personal/Family History Risk Factors ¹⁻²	Genetic Risk Factors ^{3**}
Clinical breast exam	Annually	Every 6 Months	Every 6 Months
Mammogram*	Annually	Annually	Annually
Breast MRI*	–	Annually	Annually
Consider risk-reducing surgery	–	–	Yes

*Age may vary

** Genetic risk factors may include mutations in genes including *BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, *STK11*, and *TP53*



With CARE, healthcare teams can identify high-risk patients who:

- meet NCCN Guidelines® for hereditary cancer testing³
- are at elevated risk for breast cancer based on Tyrer-Cuzick score²

WORKFLOW SOLUTIONS SUPPORTING PATIENTS AND PROVIDERS AT EVERY STEP



DIGITAL HISTORY COLLECTION AND ASSESSMENT

Suite of digital tools collect and analyze patient medical and family history and weigh against medical guidelines



GENETIC TESTING

Ordered through Ambry for qualified individuals



POST-TEST GENETIC COUNSELING

Made available to all patients



PRE-TEST EDUCATION

How genetic testing can guide personalized, proactive healthcare



RESULTS DELIVERY

Results delivered to the provider, and in most cases, to the patient, using the CARE platform



DOCUMENTATION

Transparency at each step, improving patient and provider experience

Empower your patients to take proactive steps to manage their cancer risk.

REFERENCES

1. American College of Obstetricians-Gynecologists. Practice Bulletin No. 179: Breast cancer screening. Obstet Gynecol. 2017 July
2. Adapted from American College of Radiology Practice Guidelines. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-breast.pdf>
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V2.2025. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January, 13, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.



SCAN HERE TO
LEARN MORE